Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SAR442085 |
| Synonyms | |
| Therapy Description |
SAR442085 is an antibody that binds to CD38, potentially resulting in increased antibody-dependent cellular cytotoxicity against tumor cells expressing CD38 (Blood (2022) 139 (8): 1160-1176). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SAR442085 | SAR-442085|SAR 442085 | CD38 Antibody 21 | SAR442085 is an antibody that binds to CD38, potentially resulting in increased antibody-dependent cellular cytotoxicity against tumor cells expressing CD38 (Blood (2022) 139 (8): 1160-1176). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04000282 | Phase I | SAR442085 | First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma | Completed | USA | GRC | FRA | ESP | CZE | 1 |